Plain-English translation of NCT04486352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining atezolizumab—a medication that helps your immune system fight cancer—with other targeted drugs works better for endometrial cancer that has returned or continued growing after previous treatment. Researchers will first analyze your tumor's genetic profile to match you with the most promising drug combination for your specific cancer. The goal is to find safer and more effective options for women whose cancer has not responded to standard treatments.
Endometrial cancer that comes back or doesn't respond to initial therapy is very difficult to treat, and patients need new options. This medication works by awakening the immune system to attack cancer cells, and this trial explores whether combining it with other targeted drugs—chosen based on your tumor's unique genetic makeup—can improve outcomes.
You likely qualify if…
You likely don't qualify if…
First, you will undergo genetic testing of your tumor to determine which drug combination is best suited to your cancer. Depending on your results, you will be assigned to receive one of several possible drug combinations, which you will take on a set schedule—typically beginning treatment on Day 1 of each cycle. You will have regular clinic visits to monitor how well the treatment is working, watch for side effects, and have blood tests and imaging scans as needed throughout your participation.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States